OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Immunotherapy is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers	132
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML c	119
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19	118
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma	116
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	91
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes	60
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma	56
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model	55
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies	52
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells	52
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer	51
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter ret	50
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma	49
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma	42
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist	41
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m	38
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study	38
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas	37
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach	37
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer	36
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer	36
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion	36
Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer	35
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition	35
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma	34

GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model	34
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens	34
Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration	33
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate	32
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells	31
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents	31
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors	31
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs	31
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors	31